Sotorasib Under Review for KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC
The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
All articles by Rachel Narozniak, MA
FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
FDA Greenlights Cosela to Reduce Chemotherapy-Induced Bone Marrow Suppression in ES-SCLC
The Food and Drug Administration (FDA) has approved trilaciclib (Cosela; G1 Therapeutics, Inc.).
